2.—(1) Table A of Schedule 1 is amended as follows—
(a)against the entry for “Ibuprofen”(1), there is inserted in column 3, in the entry numbered “(2)”, before the words “rheumatic pain”, the word “backache”;
(b)against the entry for “Lignocaine Hydrochloride”(2), there is inserted—
(i)in column 2, after the entry numbered “(2)”, the words “(3) 2.0 per cent”; and
(ii)in column 3, after the entry numbered “(2)”, the words “(3) External, except local ophthalmic use; for use in adults and in children aged 12 years and over; all preparations except sprays”; and
(c)against the entry for “Zinc Sulphate”, there is substituted for the entry in column 2 “(2) 0.25 per cent”, the entry “(2) 1.0 per cent”.
(2) In Table A of Schedule 1, there is inserted in column 1, at the appropriate place in the alphabetical order of the entries as they appear in that column, the entry set out in column 1 below, and, against that entry, there is inserted in columns 2, 3 and 4 the corresponding text in columns 2, 3 and 4 below:
| Column 1 | Column 2 | Column 3 | Column 4 |
|---|---|---|---|
| Substance | Maximum strength | Use, pharmaceutical form or route of administration | Maximum dose and maximum daily dose |
| Ranitidine Hydrochloride | 75mg | Tablets; for the short term symptomatic relief of heartburn, indigestion, acid indigestion and hyperacidity | 150mg (MDD). |